The chemical class designated as GP73 Activators encompasses compounds that augment the activity of GP73 by modulating the prenylation pathway, which is pivotal for the function of Rab GTPases, and by extension, influences GP73 activity. These activators operate by increasing the cellular concentrations of biochemical precursors necessary for the geranylgeranylation process. Geranylgeraniol, mevalonate, and farnesol are primary examples. Geranylgeraniol acts as a substrate for the synthesis of geranylgeranyl pyrophosphate, the lipid modification that enables Rab GTPases to anchor to cellular membranes and exert their regulatory functions. An increase in geranylgeraniol can lead to elevated levels of GGPP, thereby amplifying the geranylgeranylation of Rab GTPases. This boost in geranylgeranylation may result in enhanced GP73-mediated GTPase-activating processes due to the more robust membrane association and functioning of the Rab proteins.
Further, mevalonate plays a critical role as an intermediate in the metabolic pathway that culminates in the synthesis of isoprenoids such as GGPP. By increasing the intracellular pool of mevalonate through exogenous administration, the biosynthesis of GGPP can be amplified, thus indirectly fostering the activity of GP73 by ensuring adequate prenylation of Rab GTPases. Farnesol, another contributor to this class, serves as a precursor in the biosynthetic cascade leading to GGPP formation. It can be utilized to elevate GGPP synthesis, thereby facilitating the prenylation and proper functioning of Rab GTPases. The action of these chemicals reflects a strategic enhancement of the prenylation pathway, leading to an indirect upregulation of GP73 activity by ensuring the functional competency of Rab GTPases. This class of activators is thus characterized by their role in modulating the synthesis of key molecules that are foundational to the prenylation and subsequent activity of proteins within the Rab family, which are essential for GP73's regulatory role in cellular trafficking and lipid metabolism.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Geranylgeraniol | 24034-73-9 | sc-200858 sc-200858A | 20 mg 100 mg | $159.00 $465.00 | 14 | |
As a metabolic precursor to geranylgeranyl pyrophosphate (GGPP), geranylgeraniol supplementation can increase the availability of GGPP for protein prenylation, potentially enhancing the prenylation and proper function of Rab GTPases, which in turn could upregulate GP73 activity. | ||||||
Mevalonolactone-2-13C | 53771-22-5 | sc-235880 | 100 mg | $479.00 | ||
Mevalonolactone-2-13C is a key intermediate in the HMG-CoA reductase pathway leading to the synthesis of isoprenoids, including GGPP. By increasing the cellular supply of mevalonate, the production of GGPP may be enhanced, indirectly promoting the function of GP73 through increased Rab GTPase prenylation. | ||||||
Farnesol | 4602-84-0 | sc-204748 sc-204748A | 50 ml 100 ml | $275.00 $367.00 | 2 | |
Farnesol serves as a building block for the synthesis of GGPP. Its administration could elevate the intracellular levels of GGPP, thus indirectly facilitating GP73 activity by promoting the geranylgeranylation and function of Rab GTPases. | ||||||
GGTI 298 | 1217457-86-7 | sc-361184 sc-361184A | 1 mg 5 mg | $189.00 $822.00 | 2 | |
GGTI-298 is a geranylgeranyltransferase inhibitor used in research to study the role of protein geranylgeranylation. In a paradoxical way, blocking geranylgeranylation temporarily with GGTI-298 can lead to a compensatory upregulation of the mevalonate pathway, potentially enhancing the expression of proteins like GP73. | ||||||